

1 Admissions to a large tertiary care hospital and Omicron 2 BA.1 and BA.2 SARS-CoV-2 PCR positivity: primary, 3 contributing, or incidental COVID-19

4 Anne F. Voor in 't holt^{1#*}, Cynthia P. Haanappel^{1#}, Janette Rahamat – Langendoen², Richard
5 Molenkamp², Els van Nood¹, Leon M. van den Toorn³, Robin P. Peeters⁴, Annemarie M.C. van
6 Rossum^{1,5}, Juliëtte A. Severin¹

7 ¹Department of Medical Microbiology and Infectious Diseases, Erasmus MC University Medical
8 Center Rotterdam, The Netherlands.

9 ²Department of Viroscience, Unit Clinical Virology, Erasmus MC University Medical Center
10 Rotterdam, The Netherlands.

11 ³Department of Pulmonology, Erasmus MC University Medical Center Rotterdam, The Netherlands.

12 ⁴Department of Internal Medicine, Erasmus MC University Medical Center Rotterdam, The
13 Netherlands.

14 ⁵Department of Pediatrics, Division of Infectious Diseases and Immunology, Erasmus MC-Sophia
15 Children's Hospital University Medical Center Rotterdam, The Netherlands.

16 *#Anne F. Voor in 't holt and Cynthia P. Haanappel contributed equally to this manuscript.*

17 ***Corresponding author:** Dr. Anne F. Voor in 't holt, Department of Medical Microbiology and
18 Infectious Diseases, Erasmus MC University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015
19 GD, Rotterdam, The Netherlands. Email: a.voorintholt@erasmusmc.nl

20

21 **Running title:** COVID-19 Omicron hospital admissions

22 **Conflict of interest:** The authors report no conflicts of interest relevant to this article.

23 **Funding:** None

24

25 Abstract

26 SARS-CoV-2 Omicron variants BA.1 and BA.2 seem to show reduced clinical severity. We classified
27 172 COVID-19 Omicron patient admissions. 66.2% of patients were admitted with primary or
28 admission-contributing COVID-19. We therefore must be careful to base healthcare and public
29 health decisions on the total number of hospitalized COVID-19 patients alone.

30 **Keywords:** COVID-19, patient admission, SARS-CoV-2, epidemiology, Omicron.

31

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

32 Introduction

33 Monitoring national hospitalization rates for COVID-19 has been essential throughout the pandemic
34 to guide public health decision-making, to evaluate vaccine efficacy, and to implement a wide range
35 of other medical interventions. However, with the rapid worldwide spread of the SARS-CoV-2
36 Omicron variant of concern and increasing immunity against SARS-CoV-2, interpreting the true
37 impact of these hospitalization rates has been complicated (1, 2).

38 Signs of reduced clinical severity of Omicron compared to previous variants appeared quickly (3-8),
39 with unvaccinated patients still at the highest risk of substantial morbidity and mortality (9).
40 Omicron variants have been divided into four distinct sublineages: BA.1, BA.1.1, BA.2, and BA.3.
41 Within the Netherlands, BA2 is currently identified as the predominant strain. Given the different
42 backgrounds (*e.g.*, seroprevalence, vaccination rates) of countries reporting reduced clinical severity
43 of the Omicron variant, the monitoring of national hospitalization rates is essential to predict the
44 overload of healthcare and leads the way for measures in the community.

45 Because of the rapid spread of Omicron and the subsequent high incidence of infection in the
46 population, not all SARS-CoV-2 positive patients admitted to the hospital have been admitted solely
47 because of COVID-19. It is important to distinguish between admissions that are due to primary
48 COVID-19, admissions where COVID-19 contributes but is not the only reason (admission-
49 contributing COVID-19), or admissions where COVID-19 is not contributing to the reason of
50 admission (incidental COVID-19). Therefore, we aimed to assess and classify the cause of
51 hospitalization for COVID-19 patients identified with the Omicron variant within our hospital in order
52 to provide more insight into the clinical severity of Omicron and the COVID-19 hospital burden.

53

54 Methods

55 This study was performed in the Erasmus MC University Medical Center in Rotterdam, The
56 Netherlands (Erasmus MC). The Erasmus MC is a large tertiary care hospital with 1125 beds, with a
57 total of 121 beds at the intensive care unit (ICU). A retrospective analysis was performed on all
58 patients identified with the SARS-CoV-2 Omicron variant between 23 December 2021 and 27
59 February 2022. In this period, the testing strategy of the hospital was based on symptoms. SARS-
60 CoV-2 infection was identified by real-time transcription-mediated amplification with the Aptima®
61 SARS-CoV-2 assay using the Panther system (Hologic, Malborough, USA), or by the Xpert® Xpress
62 SARS-CoV2 assay on a GeneXpert® system (Cepheid®, Sunnyvale, USA). SARS-CoV2 positive samples
63 were further characterized by variant-specific PCR using VirSNIp (TIBmolbiol, Berlin, Germany) assays
64 targeting S371-S373 and K417 as proxy for the Omicron variant. While detection of K417N was
65 considered indicative for Omicron, S371L-S373P was considered indicative for BA.1 and S371F-S373P
66 for BA.2.

67 SARS-CoV-2 Omicron variant positive patients at admission were divided in the following categories:
68 1) patients who were hospitalized for more than 24 hours within 7 days of their first positive SARS-
69 CoV-2 PCR, 2) patients who were hospitalized for less than 24 hours within 7 days of their first
70 positive SARS-CoV-2 PCR, and 3) patients with visits only to the Erasmus MC outpatient clinic. Data
71 was collected from electronic health records (EHR) and included basic patient characteristics such as
72 age and sex, and information about country of birth, vaccination status, admission information

73 (reason of admission, wards of admission, admission date and discharge date), and oxygen therapy
74 during admission.

75 Patients with a positive SARS-CoV-2 PCR upon clinical admission or during clinical admission were
76 classified based on modified definitions developed by the National Intensive Care Evaluation (NICE)
77 Foundation (10). Classification 1) primary COVID-19; COVID-19 is the main cause for hospitalization;
78 1A) the patient is hospitalized due to COVID-19 symptoms and is receiving medical treatment for
79 these symptoms, 1B) the patient is hospitalized due to COVID-19 symptoms, does not receive
80 medical treatment, but is admitted for observation due to the underlying disease. Classification 2)
81 admission-contributing COVID-19; COVID-19 is one of the causes for hospitalization; 2A) the patient
82 is admitted for another medical cause but also has COVID-19 symptoms and is receiving medical
83 treatment for these symptoms, 2B) dysregulation of underlying disease due to COVID-19 (*e.g.*, sickle
84 cell crisis provoked by SARS-CoV-2 without respiratory involvement). Classification 3) incidental
85 COVID-19; COVID-19 is not the cause for hospitalization, the patient does not have any or only mild
86 COVID-19 symptoms, and does not receive any medical treatment for these symptoms. Classification
87 4) Indeterminate; it is unknown whether the cause of hospitalization is related to COVID-19
88 symptoms. Classifications were performed by two epidemiologists through evaluation of the
89 patient's history in the EHR. If the classification was unclear patients were assessed separately by
90 two independent epidemiologists before reaching agreement of classification.

91 This study was approved by the medical ethical research committee of the Erasmus MC (MEC-2021-
92 0845-A-0002), and was not subject to the Medical Research Involving Human Subjects Act.

93

94 **Results**

95 A total of 402 patients were identified with the Omicron variant of SARS-CoV-2 within the Erasmus
96 MC. A total of 333 adult patients were identified with the Omicron variant, of whom 287 patients
97 with variant BA.1 (86.1%), 28 patients with variant BA.2 (8.4%), and 18 patients with Omicron variant
98 for which further distinction in BA.1 or BA.2 could not be made due to low viral load in the sample
99 (5.4%). Of patients with BA.1, 39.4% had a clinical admission of more than 24 hours, 9.8% had a
100 clinical admission of fewer than 24 hours, and 50.9% had an outpatient visit only. For adult patients
101 with BA.2, 50% were clinically admitted to the hospital and 50% had an outpatient visit. Ninety-six
102 pediatric patients were identified with the Omicron variant. BA.1 was identified in 57 children
103 (82.6%), BA.2 in 16 children (15.9%), and Omicron without further distinction in BA.1 or BA.2 in 1
104 child (1.4%). Of children identified with BA.1, 26.3% were clinically admitted for more than 24 hours,
105 while 1.8% had a clinical admission of fewer than 24 hours, and 71.9% had an outpatient visit only.
106 For children with BA.2, 36.4% had a clinical admission of more than 24 hours and 63.6% only had an
107 outpatient visit.

108 One hundred seventy-two patients were hospitalized for more than 24 hours at the Erasmus MC and
109 were identified with the Omicron variant of SARS-CoV-2 at admission or during admission (Table 1).
110 Out of these 172 patients, 143 patients were identified with Omicron variant BA.1 (83.1%), 19
111 patients with BA.2 (11.0%), and 10 patients with Omicron without further distinction in BA.1 or BA.2
112 (5.8%) (Table 1).

113 **Table 1.** Characteristics of included hospitalized adult and pediatric COVID-19 patients for each
114 classification.

| | Total | Clas1: Primary COVID-19 | Clas2: Contributing COVID-19 | Clas3: Incidental COVID-19 | Clas4: Indeterminate COVID-19 |
|-------------------------------------|-------------------------|--|---|---|--|
| Adult patients (%) | 151 (100) | 68 (45.0) | 32 (21.2) | 46 (30.5) | 5 (3.3) |
| Median age (range) | 56 (18-90) | 61 (18-90) | 51 (18-82) | 55 (22-90) | 23 (22-49) |
| Male gender (%) | 82 (54.3) | 35 (51.5) | 20 (62.5) | 25 (54.3) | 2 (40) |
| Country of birth | | | | | |
| The Netherlands | 90 (60.4) ² | 44 (65.7) ³ | 18 (56.3) | 26 (57.8) ³ | 2 (40) |
| Other | 59 (39.6) ² | 23 (34.3) ³ | 14 (43.8) | 19 (42.2) ³ | 3 (60) |
| Solid organ recipient (%) | 23 (15.2) | 16 (23.5) | 6 (18.8) | 1 (2.2) | na |
| Lung (%) | 9 (6.0) | 8 (11.8) | 1 (3.1) | 0 (0) | na |
| Kidney (%) | 13 (8.6) | 8 (11.8) | 4 (12.5) | 1 (2.2) | na |
| 28-day in-hospital mortality (%) | 12 (7.9) | 7 (10.3) | 1 (3.1) | 4 (8.7) | 0 (0) |
| Vaccinated ¹ | 55 (53.9) ⁴ | 37 (61.7) ⁵ | 7 (30.4) ⁶ | 11 (57.9) ¹¹ | na |
| Received booster vaccination | 33 (34.7) ⁷ | 25 (43.1) ⁸ | 3 (14.3) ⁹ | 5 (31.3) ¹² | na |
| BA.1 lineage (%) | 127 (84.1) | 52 (76.5) | 27 (84.4) | 43 (93.5) | 5 (100) |
| BA.2 lineage (%) | 14 (9.3) | 9 (13.2) | 2 (6.3) | 3 (6.5) | 0 (0) |
| Oxygen therapy during admission | 74 (50.7) ¹⁰ | 56 (82.4) | 13 (40.6) | 5 (10.9) | na |
| ICU during admission (%) | 13 (8.6) | 6 (8.8) | 1 (3.1) | 6 (13.0) | 0 (0) |
| ICU as admission department (%) | 10 (6.6) | 5 (7.4) | 0 (0) | 5 (10.9) | 0 (0) |
| Pediatric patients (%) | 21 (100) | 4 (19.0) | 6 (28.6) | 8 (38.1) | 3 (14.3) |
| Median age (range) | 3 (0-17) | 4 (0-8) | 3 (0-13) | 2 (0-7) | 15 (12-17) |
| Male gender (%) | 12 (57.1) | 2 (50) | 5 (83.3) | 4 (50) | 1 (33.3) |
| Country of birth | | | | | |
| The Netherlands | 19 | 4 (100) | 5 (83.3) | 7 (87.5) | 3 (100) |
| Other | 2 | 0 (0) | 1 (16.7) | 1 (12.5) | 0 (0) |
| 28-day in-hospital mortality (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| BA.1 lineage (%) | 16 (76.2) | 2 (50) | 5 (83.3) | 7 (87.5) | 2 (66.7) |
| BA.2 lineage (%) | 5 (23.8) | 2 (50) | 1 (16.7) | 1 (12.5) | 1 (33.3) |
| Oxygen therapy during admission (%) | 8 (38.1) | 4 (100) | 3 (50) | 1 (12.5) | na |
| ICU during admission (%) | 6 (28.6) | 1 (25) | 3 (50) | 2 (25) | 0 (0) |
| ICU as admission department (%) | 6 (28.6) | 1 (25) | 3 (50) | 2 (25) | 0 (0) |

115 Abbreviations: ICU; intensive care unit, na; not available, clas; classification.

116 ¹Received 2 COVID-19 vaccinations (Pfizer/BioNTech, Moderna or AstraZeneca) or 1 vaccination (Johnson &
117 Johnson's Janssen), ²for 2 patients this was unknown, ³for 1 patient this was unknown, ⁴for 49 patients this
118 was unknown, ⁵for 8 patients this was unknown, ⁶for 9 patients this was unknown, ⁷for 56 patients this was
119 unknown, ⁸for 10 patients this was unknown, ⁹for 11 patients this was unknown, ¹⁰for 5 patients this was
120 unknown, ¹¹for 27 patients this was unknown, ¹²for 30 patients this was unknown.

121 Discussion

122 This study assessed and classified the cause of hospitalization of 172 SARS-CoV-2 positive patients.
123 We observed that less than 50% of adult Erasmus MC patients identified with the Omicron variant
124 were clinically admitted for more than 24 hours. Of these, 45% were primary COVID-19 cases, 21%
125 were contributing, and 31% were incidental. Primary COVID-19 patients were older, had a higher 28-
126 day in-hospital mortality rate, and showed more BA.2. However, they had higher COVID-19
127 vaccination and booster rates compared to incidental COVID-19 cases. Additionally, primary COVID-
128 19 and admission-contributing COVID-19 were more frequently observed among transplant
129 recipients. These groups differ thereby from patients with incidental COVID-19 Omicron patients.
130 This is in line with the study conducted by Sun *et al.* (11).

131 Studies in pediatric patients show that the number of admitted pediatric patients with the Omicron
132 variant is higher compared to previous variants (12). In this study, we did not register any in-hospital
133 mortality among pediatric patients and small numbers of ICU admissions suggesting no increased
134 clinical severity, even though incidence among children was high in the community.

135 Initial studies on patients with the Omicron variant mainly assessed the change in clinical severity of
136 hospitalized COVID-19 patients. However, these studies did not differentiate between primary and
137 incidental COVID-19, hereby providing a general conclusion for all patients, while inherent
138 differences are to be expected between patient populations (3, 4) Studies have reported between
139 17.6% and 19.7% of hospitalized COVID-19 patients with the Omicron variant receiving oxygen
140 therapy and an in-hospital mortality between 2.7 and 5.8%, while we registered over 80% of primary
141 COVID-19 patients receiving oxygen therapy and a mortality of 10.3%(4, 6) This could be attributed
142 to the larger proportion of immunocompromised patients among primary COVID-19 admissions.

143 We suggest assessing the risk of severe disease caused by SARS-CoV-2 differently for primary COVID-
144 19 compared to incidental COVID-19 patients. These data are of interest to clinicians but also to
145 stakeholders such as hospital managers, infection prevention and control (IPC) practitioners, public
146 health professionals, and the general public. Weighing these patient groups separately in terms of
147 the attributed burden for healthcare could have implications for public health and healthcare
148 decision-making. This could include maintaining non-pharmaceutical interventions such as masks for
149 patients at risk of becoming a primary COVID-19 patient (11).

150 Although both primary and incidental COVID-19 hospitalizations have implications for workload and
151 isolation capacity, incidental COVID-19 in patients generally interferes less with continuity of care.
152 Counting patients with incidental COVID-19 as COVID-19 admissions therefore gives a skewed image
153 of hospital workload and the COVID-19 burden we are currently dealing with. Therefore, one should
154 be careful to base healthcare and public health decisions, in the evolving landscape of COVID-19 on
155 the total number of hospitalized COVID-19 patients alone.

156

157 References

158 1. Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, et al. Rapid epidemic
159 expansion of the SARS-CoV-2 Omicron variant in southern Africa. *Nature*. 2022.

- 160 2. Parkkali M. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern: World
161 Health Organization; 2021 [updated 26 November 2021. Available from: [https://www.who.int/news-](https://www.who.int/news-room/statements/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern)
162 [room/statements/26-11-2021-classification-of-omicron-\(b.1.1.529\)-sars-cov-2-variant-of-concern](https://www.who.int/news-room/statements/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern).
- 163 3. Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the
164 clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. *The Lancet*.
165 2022;399(10323):437-46.
- 166 4. Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and
167 Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared
168 With Previous Waves. *Jama*. 2022;327(6):583-4.
- 169 5. Kahn F, Bonander C, Moghaddassi M, Rasmussen M, Malmqvist U, Inghammar M, et al. Risk
170 of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age
171 and comorbidities – surveillance results from southern Sweden, July 2021 to January 2022.
172 *Eurosurveillance*. 2022;27(9):2200121.
- 173 6. Jassat W, Karim SA, Mudara C, Welch R, Ozougwu L, Groome M, et al. Clinical Severity of
174 COVID-19 Patients Admitted to Hospitals in Gauteng, South Africa During the Omicron-Dominant
175 Fourth Wave. *Lancet (preprint)*. 2021.
- 176 7. Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND, Xu R. Comparison of outcomes from
177 COVID infection in pediatric and adult patients before and after the emergence of Omicron.
178 *medRxiv*. 2022.
- 179 8. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative
180 analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and
181 delta (B.1.617.2) variants in England: a cohort study. *The Lancet*.
- 182 9. Luring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al. Clinical
183 severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha
184 SARS-CoV-2 variants in the United States: prospective observational study. *Bmj*. 2022;376:e069761.
- 185 10. The National Intensive Care Evaluation (NICE) Foundation. COVID-19 infecties op de IC's: de
186 verdeling in 'COVID-19 reden van opname' voor alle patiënten met een SARS-CoV-2 infectie 2022
187 [Available from: <https://www.stichting-nice.nl/covid-19-op-de-ic.jsp>.
- 188 11. Sun J, Zheng Q, Madhira V, Olex AL, Anzalone AJ, Vinson A, et al. Association Between
189 Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US.
190 *JAMA Intern Med*. 2022;182(2):153-62.
- 191 12. Belay ED, Godfred-Cato S. SARS-CoV-2 spread and hospitalisations in paediatric patients
192 during the omicron surge. *Lancet Child Adolesc Health*. 2022.